Overview:
The
global precision medicine
market size is witnessing unprecedented growth due to people turning
their focus more on personal healthcare. It could attain an astonishing CAGR of
12.5% during the forecast period (2023-2032).
The
Precision Medicine Market is experiencing robust growth driven by advancements
in genomic technologies and personalized healthcare. It encompasses tailored
medical treatments based on individual patient characteristics, including
genetics, lifestyle, and environment. Key factors propelling market expansion
include rising chronic diseases, increasing demand for targeted therapies, and
government initiatives promoting precision medicine adoption. Technological
innovations like next-generation sequencing and bioinformatics are enhancing
diagnostic capabilities and treatment efficacy. Additionally, collaborations
between pharmaceutical companies, research institutions, and healthcare
providers are fostering market growth. However, challenges such as high costs,
data privacy concerns, and regulatory complexities pose barriers to widespread
adoption.
The
Precision Medicine Market is experiencing a transformative shift driven by
advancements in personalized medicine. Personalized medicine, also
known as precision medicine, tailors medical treatment and interventions to
individual characteristics, such as genetic makeup, lifestyle, and environment.
This approach contrasts with traditional one-size-fits-all medical practices,
offering more targeted and effective solutions for patients. The burgeoning
interest in personalized medicine stems from its potential to revolutionize
healthcare by delivering treatments that are optimized for each patient's
unique biology and circumstances. As a result, the Precision Medicine Market is
rapidly expanding, fueled by growing investments in research and development,
as well as increasing adoption by healthcare providers and patients alike.
Market Insights:
Mergers,
acquisitions, collaborations and other strategies dominate the market
substantially when it comes to strategic decisions. For instance, Roche
purchased Foundation Machine to better their portfolio. On the other hand, New
Medicine Partners is trying to increase their market reach by proposing a plan
based on personalized medicines to Kazakhstan officials to develop a plant
there.
Prominent
global precision medicine
companies include Abbott Laboratories (USA), Ab-Biotics SA (USA),
Almac Group Ltd. (UK), Asuragen Inc (USA), Biobase GmbH (Germany), Biomérieux
SA (France), Caris Life Sciences (USA), Cepheid Inc. (USA), Cetics Healthcare
Technologies Gmbh (Germany), GE Healthcare (USA), GlaxoSmithKline PLC (UK),
Healthcore Inc. (USA), IBM (USA), Innventis (Israel), Intel Corporation (USA),
Johnson & Johnson (USA), Laboratory Corporation Of America Holdings (USA),
Medtronic (USA), Molecular Health GmbH (Germany), Novartis (Switzerland),
Pfizer Inc. (USA), Qiagen (Germany), Quest Diagnostics Inc (USA), Randox
Laboratories Ltd. (UK), Sanofi Pharma (France), Takeda Pharmaceutical Company
Limited (Japan), Teva Pharmaceutical Industries Ltd. (Israel), and others.
Industry Trends:
Precision
medicine is showing great promise for the cure of the Alzheimer’s disease. Two
new drugs are waiting on the sideline for final approval; one called BAN2401
and the other Anavex 2-73. BAN2401’s use on patients shows a reduction in
generation of proteins called amyloid plaques that cause memory loss.
Recently,
an article published in SLAS Technology (Society for Laboratory Automation and
Screening) revealed that artificial intelligence (AI) is all set to impact
precision medicine industry significantly as it can efficiently analyze small
datasets and assist in the optimal design of drug combinations.
Segmentation:
The
global precision medicine market can be segmented by ecosystem, sub-market, and
therapeutics.
Based
on the ecosystem, the precision medicine market can be segmented into clinical
laboratories, diagnostic tool companies, healthcare IT/ big data companies, and
pharma & biotech companies. Diagnostic tools segment has the largest market
volume.
Sub-market
segment of the precision medicine can be segmented by biomarker-based test,
companion diagnostics, molecular diagnostics, pharmacogenomics, targeted
therapeutics, and others. Company diagnostics is leading the segment.
Therapeutics-based
segmentation of the precision medicine market includes cancer/oncology,
cardiovascular disease, central nervous system, infectious diseases, and
others.
Regional Analysis:
Region-specific
analysis of the precision medicine market encompasses North America, Europe,
Asia Pacific (APAC), and the Middle East & Africa (MEA).
North
America is the largest market for global precision medicine. The region has
superior infrastructure, both in healthcare and biotechnology. It sets up the
zone perfectly for research and developments assisting further in new product
development.
Europe
is the second-largest market for global precision medicine. Various investors
are taking an interest in the sector and is helping in the development of new
drugs. However, the developing regions market particularly, the APAC will be
the fastest growing and is likely to be the key to the future. But the MEA
region may not find much thrust due to but can expect steady growth.
Related reports-
For more information, Please Visit us @ Market Research Future
No comments:
Post a Comment